Is The Trade Desk the Best Advertising Stock Now?
The worldly backdrop is now shrouded in heavy uncertainty and…
Buy
56
CTEV Quote, Financials, Valuation and Earnings
Last price:
$23.11
Seasonality move
:
20.46%
Day range:
$22.15 - $23.43
52-week range:
$4.80 - $31.01
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.39x
P/B ratio:
4.32x
Volume:
45.2K
Avg. volume:
72.8K
1-year change:
-2.65%
Market cap:
$363M
Revenue:
$930.6M
EPS (TTM):
-$101.54
Analysts' Opinion
-
Consensus RatingClaritev has received a consensus rating of Hold. The company's average rating is a Hold based on 0 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target DownsideAccording to analysts' consensus price target of $19.00, Claritev has an estimated downside of -10.75% from its current price of $22.41.
-
Price Target UpsideAccording to analysts, the highest upside price target is $19.00 representing -100% upside increase from its current price of $22.41.
Fair Value
-
According to the consensus of 1 analyst, Claritev has -10.75% downside to fair value with a price target of $19.00 per share.
CTEV vs. S&P 500
-
Over the past 5 trading days, Claritev has overperformed the S&P 500 by 11.35% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Claritev does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Claritev revenues have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter Claritev reported revenues of $232.1M.
Earnings Growth
-
Claritev earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Claritev reported earnings per share of -$8.49.
Enterprise value:
4.9B
EV / Invested capital:
--
Price / LTM sales:
0.39x
EV / EBIT:
--
EV / Revenue:
5.23x
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
-463.42x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$691.2M
Return On Assets:
-27.85%
Net Income Margin (TTM):
-176.85%
Return On Equity:
-218.02%
Return On Invested Capital:
-31.15%
Operating Margin:
5.66%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $1.1B | $961.5M | $930.6M | $244.1M | $232.1M | |
| Gross Profit | $875.6M | $726.1M | $691.2M | $183.5M | $175M | |
| Operating Income | $334.2M | $170M | $98.9M | $40.8M | $13.1M | |
| EBITDA | $158.3M | $651.9M | -$1B | $159.3M | $4.9M | |
| Diluted EPS | -$36.00 | -$5.82 | -$101.54 | -$1.94 | -$8.49 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $208.9M | $319.3M | $446.7M | $193.6M | $175.5M | |
| Total Assets | $8.3B | $8.2B | $7.4B | $7B | $5.2B | |
| Current Liabilities | $112.5M | $141.9M | $175.8M | $166.7M | $213.8M | |
| Total Liabilities | $5.7B | $5.9B | $5.6B | $5.3B | $5.1B | |
| Total Equity | $2.6B | $2.3B | $1.8B | $1.7B | $84M | |
| Total Debt | $4.6B | $4.9B | $4.8B | $4.5B | $4.5B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $372.4M | $171.7M | $107.6M | $27.7M | -$33.4M | |
| Cash From Investing | -$104.4M | -$249.8M | -$118.1M | -$31.3M | -$30.4M | |
| Cash From Financing | -$115.7M | -$181M | -$41.3M | -$22.5M | -$3.6M | |
| Free Cash Flow | $282.6M | $62.9M | -$10.5M | -$3.6M | -$63.8M | |
CTEV
Sector
Market Cap
$363M
$34.4M
Price % of 52-Week High
72.27%
44.25%
Dividend Yield
0%
0%
Shareholder Yield
8.37%
-0.82%
1-Year Price Total Return
-2.65%
-39.44%
Beta (5-Year)
--
0.738
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$21.33
200-day SMA
Buy
Level
$14.08
Bollinger Bands (100)
Buy
Level
11.54 - 23.68
Chaikin Money Flow
Buy
Level
152.2K
20-day SMA
Buy
Level
$20.65
Relative Strength Index (RSI14)
Buy
Level
58.51
ADX Line
Buy
Level
18.67
Williams %R
Neutral
Level
-21.3592
50-day SMA
Buy
Level
$21.73
MACD (12, 26)
Buy
Level
2.77
25-day Aroon Oscillator
Buy
Level
60
On Balance Volume
Neutral
Level
249.8K
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-1.3083)
Sell
CA Score
(Annual)
Level (-3.0964)
Buy
Beneish M-Score
(Annual)
Level (-4.0616)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (3.6518)
Buy
Piotroski F Score
(Annual)
Level (4)
Sell
Quality Ratio Score
Level (2)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Claritev Corp is a healthcare technology, data, and insights company focused on improving transparency, affordability, and quality. The company provides tech-enabled solutions and services to interpret clients' needs and customize solutions that combine its payment integrity, network-based, and analytics-based services. The Company's focus is being a value-added provider of data analytics and technology-enabled end-to-end cost management, payment, and revenue integrity solutions to the U.S. healthcare industry.
Stock Forecast FAQ
In the current month, CTEV has received 0 Buy ratings 1 Hold ratings, and 0 Sell ratings. The CTEV average analyst price target in the past 3 months is $19.00.
-
Where Will Claritev Stock Be In 1 Year?
According to analysts, the consensus estimate is that Claritev share price will drop to $19.00 per share over the next 12 months.
-
What Do Analysts Say About Claritev?
Analysts are divided on their view about Claritev share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Claritev is a Sell and believe this share price will rise from its current level to $19.00.
-
What Is Claritev's Price Target?
The price target for Claritev over the next 1-year time period is forecast to be $19.00 according to 1 Wall Street analyst, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is CTEV A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Claritev is a Hold. 1 of 1 analysts rates the stock a Hold at this time.
-
How Can I Buy Shares Of CTEV?
You can purchase shares of Claritev via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Claritev shares.
-
What Is The Claritev Share Price Today?
Claritev was last trading at $23.11 per share. This represents the most recent stock quote for Claritev. Yesterday, Claritev closed at $22.41 per share.
-
How To Buy Claritev Stock Online?
In order to purchase Claritev stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is it Too Late to Buy Gold?
Amid deep uncertainties about the future of the US economy,…
Is NextEra Energy a Stock to Hold Forever?
NextEra Energy (NYSE:NEE) share price sold off hard in recent…
Stock Ideas
Buy
61
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
54
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 37x
Alerts
Sell
39
RGC alert for Apr 29
Regencell Bioscience Holdings [RGC] is down 10.02% over the past day.
Buy
76
EXOD alert for Apr 29
Exodus Movement [EXOD] is down 2.47% over the past day.
Sell
48
SBGSY alert for Apr 29
Schneider Electric SE [SBGSY] is down 0.19% over the past day.
